BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:VC005 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of VC005\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07796191-1511@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:VC005: Phase 1 readout est. (NCT07796191)
DESCRIPTION:VC005\, phase 1.\nStudy: Drug-drug Interactions Studies of VC00
 5 Tablets in Healthy Adult Subjects\nEstimated primary completion: 30 Nove
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vc005#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07796191
URL:https://assetmemo.bio/drug/vc005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07598383-1511@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270222
DTEND;VALUE=DATE:20270223
SUMMARY:VC005: Phase 2 readout est. (NCT07598383)
DESCRIPTION:VC005\, phase 2\, Atopic Dermatitis.\nStudy: A Multicenter\, Ra
 ndomized\, Double-blind\, Vehicle Controlled Phase II Clinical Study to Ev
 aluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to
  Moderate Atopic Dermatitis\nEstimated primary completion: 22 February 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/vc005#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07598383
URL:https://assetmemo.bio/drug/vc005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07828639-1511@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:VC005: Phase 1/2 readout est. (NCT07828639)
DESCRIPTION:VC005\, phase 1/2.\nStudy: A Study of VC005 Tablets in Adolesce
 nt Subjects With Non-Segmental Vitiligo\nEstimated primary completion: 30 
 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vc005#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07828639
URL:https://assetmemo.bio/drug/vc005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07172347-1511@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:VC005: Phase 2 readout est. (NCT07172347)
DESCRIPTION:VC005\, phase 2.\nStudy: Efficacy and Safety Phase II Study of 
 VC005 Tablets in Subjects With Non-segmental Vitiligo\nEstimated primary c
 ompletion: 30 August 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/vc005#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07172347
URL:https://assetmemo.bio/drug/vc005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07172360-1511@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:VC005: Phase 3 readout est. (NCT07172360)
DESCRIPTION:VC005\, phase 3.\nStudy: Efficacy and Safety Phase III Clinical
  Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.\nE
 stimated primary completion: 30 August 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/vc005#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07172360
URL:https://assetmemo.bio/drug/vc005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06723080-1511@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:VC005: Phase 3 readout est. (NCT06723080)
DESCRIPTION:VC005\, phase 3\, Atopic Dermatitis.\nStudy: Phase III Clinical
  Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic D
 ermatitis\nEstimated primary completion: 30 August 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/vc005#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06723080
URL:https://assetmemo.bio/drug/vc005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07762443-1511@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:VC005: Phase 1 readout est. (NCT07762443)
DESCRIPTION:VC005\, phase 1.\nStudy: A Phase I Study of VC005 Tablets in Ad
 olescent Subjects With Severe Alopecia Areata\nEstimated primary completio
 n: 30 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 vc005#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07762443
URL:https://assetmemo.bio/drug/vc005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07592585-1511@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280530
DTEND;VALUE=DATE:20280531
SUMMARY:VC005: Phase 3 readout est. (NCT07592585)
DESCRIPTION:VC005\, phase 3\, Atopic Dermatitis.\nStudy: Phase III Clinical
  Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Derm
 atitis\nEstimated primary completion: 30 May 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/vc005#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07592585
URL:https://assetmemo.bio/drug/vc005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07749716-1511@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:VC005: Phase 2 readout est. (NCT07749716)
DESCRIPTION:VC005\, phase 2.\nStudy: Phase II Clinical Study of VC005 Table
 ts in Subjects With Severe Alopecia Areata\nEstimated primary completion: 
 30 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vc0
 05#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7749716
URL:https://assetmemo.bio/drug/vc005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
